Patent Application
20120061396
The present invention generally relates to the field of packaging for pharmaceutical products such as pills, capsules, and the like and, more particularly, to packaging arrangements that facilitate the disposal of pharmaceutical products (e.g., to reduce the potential of illicit usage of unused pharmaceutical product).
Abuse, misuse, and overdose of pharmaceutical products (e.g., pain management drugs) are serious health concerns that affect many people on a daily basis all over the world. For instance, diversion and subsequent misuse or abuse may occur when a patient gets a prescription for a pharmaceutical product and does not use all of the pharmaceutical product for whatever reason (e.g., a doctor may prescribe a pharmaceutical product for a patient and advise the patient to take the pharmaceutical product on an “as needed” basis; a patient may be advised to use an entire prescribed amount of pharmaceutical product, but may unilaterally decide to discontinue use of the pharmaceutical product as one or more symptoms disappear). In any case, remaining pharmaceutical product may be ultimately acquired by an individual other than for whom the pharmaceutical product was originally prescribed (e.g., transferred by the original patient to another individual, such as family member or friend; stolen).
While unused pharmaceutical product may be disposed of in the trash, this may not be viewed by some as a secure method of disposal. In some states, “take back” programs have been instituted, allowing users to request shipping materials in order to ship used or unused pharmaceutical product (e.g., patches, pills, capsules) to a certified disposal company. These programs are costly and require several actions by the patient at multiple times.
The present invention embodies a pharmaceutical product supply. This pharmaceutical product supply includes a container, a pharmaceutical product receiver, and pharmaceutical product. More specifically, the pharmaceutical product receiver includes a plurality of pockets or receptacles, and may be disposed within the container. Pharmaceutical product is enclosed within at least one of these receptacles (e.g., pharmaceutical product may be contained with each of the receptacles). Generally, the pharmaceutical product receiver may be locked to at least some degree within the container to facilitate disposal of the pharmaceutical product supply, for instance at a time when some of the pharmaceutical product may have been removed from the pharmaceutical product receiver but prior to utilizing all of the pharmaceutical product originally provided with the pharmaceutical product receiver.
A first aspect of the present invention is embodied by a pharmaceutical product supply of the above-noted type, but where a mechanical lock is provided between the container and the pharmaceutical product receiver. At a time when the pharmaceutical product receiver is positioned within the container, having the mechanical lock being disposed in an activated state will at least restrain this pharmaceutical product receiver from being removed from the container (e.g., locking the pharmaceutical product receiver within the container). Moreover, the mechanical lock may be configured so as to be permanently retained in its activated (e.g., locking or locked) state.
A number of feature refinements and additional features are applicable to the first aspect of the present invention. These feature refinements and additional features may be used individually or in any combination. As such, each of the following features that will be discussed may be, but are not required to be, used with any other feature or combination of features of the first aspect of the present invention. The following discussion pertains to this first aspect, up to the start of the discussion of a second aspect of the present invention.
The mechanical lock may be manually activated, may be activated on an exterior of the container, or both. For instance, a user may engage one or more buttons or the like located on an exterior of the container to dispose the mechanical lock in its activated state. In one embodiment, the mechanical lock utilizes a projection/aperture arrangement (e.g., a dead-bolt type lock). The projection may be associated with one of the container and the pharmaceutical product receiver, while the aperture may be associated with the other of the container and the pharmaceutical product receiver. In one embodiment, the projection is associated with the container (e.g., integrally formed therewith, such that there is no joint between the projection and an adjoining portion of the container), while the aperture is associated with the pharmaceutical product receiver (e.g., a hole of any appropriate configuration that extends completely through a tray of a blister card). Generally, disposing at least part of the projection at least partially within the aperture may dispose the mechanical lock in its activated state (e.g., the projection may indeed extend completely through the aperture when the mechanical lock is in its activated state).
The projection may be of any appropriate size, shape, configuration, and/or type. Representative projections include without limitation a detent, a locking pin, a locking tab, a locking post, or the like. The projection may be a movable structure, for instance to dispose or change the projection from an unlocked configuration to a locked configuration. Disposing the projection in its locked configuration may place the mechanical lock in its activated state. In one embodiment, the projection is unable to return from its locked configuration to its unlocked configuration (e.g., once the projection has been disposed in its locked configuration, it may be precluded from returning to its unlocked configuration). Although this may be provided by the manner in which the projection is integrated by, for instance, the container as will be discussed below, a latch may be disposed within the interior of the container to restrain the projection from moving from its locked configuration back to its unlocked configuration. Such a latch may be integrally formed with the container (e.g., of a one-piece construction, such that there is no joint of any kind between the latch and the container). The latch may be integrated with the container, and may be engageable with the pharmaceutical product receiver. When in a latched configuration, the latch may prevent the projection from returning to an unlocked configuration.
Any appropriate motion may be utilized to change the projection from its unlocked configuration to its locked configuration. The projection may be characterized as being movably interconnected with the container. Any appropriate movable interconnection may be utilized, for instance a hinge between the container and the projection (e.g., a living hinge). One representative movable interconnection between the projection and the container is a pivotal interconnection.
The projection in the noted projection/aperture arrangement for the mechanical lock may also be in the form of a stationary structure. The projection may extend from the container (e.g., within an interior thereof) and may remain in a stationary position relative to at least part of the container (e.g., the surface from which the projection extends). As such, the pharmaceutical product receiver may include the aperture. At least one actuator may be utilized to move the pharmaceutical product receiver relative to the container to dispose the mechanical lock in an inactive state. In one embodiment, one or more actuators of the container are engaged or activated to exert a lifting force on the pharmaceutical product receiver that directs the projection out of the aperture. Thereafter, the pharmaceutical product receiver may be removed from the interior of the container, for instance by withdrawing the pharmaceutical product receiver out through an open end of the container.
Any appropriate number of actuators of the above-noted type may be utilized. One or more actuators may be incorporated at any appropriate location on the container and in any appropriate manner. A pair of actuators may be disposed on opposing sides or side panels of the container, and furthermore may be disposed in opposing relation (e.g., directly across from one another; such that a user exerts collinear/opposing forces on a pair of actuators). In any case, when the pharmaceutical product receiver is appropriately positioned within the container and without engaging the actuator(s), the projection of the container may extend at least partially within the aperture of the pharmaceutical product receiver to dispose the mechanical lock in its activated state. As such, the pharmaceutical product receiver should not be able to be removed from the container in the intended manner.
The pharmaceutical product receiver may be repeatedly removed from and inserted back into the container in the above-described manner. When disposal of the pharmaceutical product supply is desired, at least one of these actuators may be disabled and/or at least partially removed from the container (e.g., utilizing a score or the like between the actuator and the remainder of the container; a “tear away” configuration for such an actuator) such that the actuator(s) may no longer be used to dispose the mechanical lock in an inactive state. As such, the mechanical lock should then remain in an activated state to reduce the potential of the pharmaceutical product receiver being removed from the container.
The aperture of the noted projection/aperture arrangement may be associated with the pharmaceutical product receiver as noted. The pharmaceutical product receiver may be in the form of a blister card, and the aperture may be incorporated by a tray for the blister card. Although the aperture may extend completely through the pharmaceutical product receiver, the aperture could be in the form of a concave depression or the like on an exterior surface of the pharmaceutical product receiver (or whatever structure incorporates the aperture in the projection/aperture arrangement for the mechanical lock).
One configuration of the pharmaceutical product supply uses a locking member (e.g., a locking tab, flap, or the like) that is movably interconnected with the container, along with an aperture that extends through the pharmaceutical product receiver. The interaction between this locking member and the aperture may define the activated state for the mechanical lock.
The locking member may be movably interconnected with the container in any appropriate manner (e.g., pivotally), for instance using a hinge (e.g., a living hinge). The locking member may be located on an exterior of the container when in an unlocked configuration, for instance such that it is coplanar with a panel of the container that incorporates the locking member. In any case, the locking member may extend within an interior of the container when it is disposed in its locked configuration (e.g., by a user pressing inwardly (in a direction of the interior of the container) on the locking member). This movement of the locking member into its locked configuration may direct the locking member into/through the aperture of the pharmaceutical product receiver to dispose the mechanical lock in its activated state.
Once the locking member has been changed from its unlocked configuration to its locked configuration, the pharmaceutical product supply may be configured such that the locking member is thereafter unable to return to its unlocked configuration. This should reduce the potential of the pharmaceutical product receiver being able to be removed from the interior of the container. In one embodiment, the container includes a latch that restrains the locking member from moving from its locked configuration back to its unlocked configuration. Such a latch may be disposed within the interior of the container, may be integrally-formed with the container (e.g., such that there is no joint between the locking member and an adjoining portion of the container), or both. The latch may be integrated with the container, and may be engageable with the pharmaceutical product receiver. When in a latched configuration, the latch may prevent the latching member from returning to an unlocked configuration.
The manner in which the locking member is movably interconnected with the container may keep the locking member from moving back to its unlocked configuration. Consider the case where the locking member moves within a first dimension when changing from its unlocked configuration to its locked configuration, and where the pharmaceutical product receiver moves relative to the container in a second dimension when the pharmaceutical product receiver is removed from the container. Having the first and second dimensions be different from one another may preclude the locking member from returning from its locked configuration back to its unlocked configuration. If the pharmaceutical product receiver is characterized as moving in a longitudinal dimension when being withdrawn from the container (e.g., through an open end thereof), the locking member may be characterized as moving in a lateral dimension when being changed from its unlocked configuration to its locked configuration (e.g., pivoting in a side-to-side fashion in relation to the structure of the container). Stated another way, the locking member may be movably integrated with the container such that when the pharmaceutical product receiver is disposed within the container and when the locking member is disposed within the aperture, exerting a force on the pharmaceutical product receiver in an attempt to withdraw the pharmaceutical product receiver out from the container may exert a force on the locking member, but this force is not exerted in a direction that would tend to move the locking member back toward its unlocked configuration.
Another configuration of the pharmaceutical product supply uses at least one release actuator. Activating each such release actuator allows the pharmaceutical product receiver to be removed from the container (e.g., for a dosing event). One or more of the release actuators may be disabled and/or at least partially removed from the container (e.g., utilizing a tear-away configuration) so as to maintain the mechanical lock in its activated state when the pharmaceutical product receiver is appropriately positioned within the container. As such, a common component (e.g., at least one release actuator) may be utilized in selectively retaining the pharmaceutical product receiver within the container, and may also be utilized to more permanently lock the pharmaceutical product receiver within the container. In this arrangement, the mechanical lock may be in the form of a projection that extends within an interior of the container and into/through an aperture formed in the pharmaceutical product receiver.
A second aspect of the present invention is embodied by a pharmaceutical product supply of the type addressed at the introduction of this Summary, but where the container includes a movable locking member and where the pharmaceutical product receiver includes an aperture. The movable locking member may be disposed in a locked configuration where the locking member extends at least into the aperture of the pharmaceutical product receiver (e.g., to provide resistance to removal of the pharmaceutical product receiver out from the interior of the container).
A number of feature refinements and additional features are applicable to the second aspect of the present invention. These feature refinements and additional features may be used individually or in any combination. As such, each of the following features that will be discussed may be, but are not required to be, used with any other feature or combination of features of the second aspect of the present invention. The following discussion pertains to this second aspect, up to the start of the discussion on a third aspect of the present invention.
The locking member may be movably interconnected with the container in any appropriate manner, for instance using a hinge of any appropriate type (e.g., a living hinge). The locking member may also undergo any appropriate motion or combination of motions when being disposed in its locked configuration. In one embodiment, the locking member is pivoted relative to a remainder of the container when being disposed in its locked configuration.
The locking member may be movable from an unlocked configuration to its locked configuration. In its unlocked configuration, the locking member may define a portion of the perimeter of the container (e.g., by being disposed coplanar with a panel of the container that incorporates the locking member). Stated another way, the locking member may be characterized as being disposed on an exterior of the container when in its unlocked configuration, and may be characterized as extending within an interior of the container when disposed in its locked configuration. In one embodiment and once the locking member has been disposed in its locked configuration, the locking member may be unable to return to its unlocked configuration (e.g., a mechanical lock incorporating the locking member and aperture may be configured so as to be permanently retained in an activated or locked state). This may be realized in the manner addressed above in relation to the first aspect (e.g., by the manner in which the locking member is incorporated by the container, by incorporating an interior latch, or both).
A third aspect of the present invention is embodied by a pharmaceutical product supply of the type addressed at the introduction of this Summary, but where the container includes a first locking member and at least one release actuator, and where the pharmaceutical product receiver includes a second locking member. The first and second locking members may collectively define a mechanical lock. Activating one or more release actuators disposes this mechanical lock in an inactive state. Disabling and/or at least partially removing at least one release actuator eliminates an ability of such a release actuator to dispose the mechanical lock in its inactive state.
A number of feature refinements and additional features are applicable to the third aspect of the present is invention. These feature refinements and additional features may be used individually or in any combination. As such, each of the following features that will be discussed may be, but are not required to be, used with any other feature or combination of features of the third aspect of the present invention. The following discussion pertains to at least to this third aspect.
When the mechanical lock is in its inactive state, the pharmaceutical product receiver may be removed from the container, for instance by being withdrawn out from an interior of the container through an open end of the container. When the pharmaceutical product receiver is appropriately positioned within the container, and further when at least one release actuator has been disabled and/or at least partially removed, the mechanical lock is maintained in an active state (e.g., the mechanical lock may be configured so as to be permanently retained in an active, activated, or locked state). Having the mechanical lock in an active state reduces the potential that the pharmaceutical product receiver may be removed from the container in the intended manner.
The first locking member associated with the container may be in the form of the projection discussed above in relation to the first aspect. The second locking member associated with the pharmaceutical product receiver may be in the form of an aperture that extends at least partially through the pharmaceutical product receiver and as discussed above in relation to the first aspect, and thereby encompassing extending completely through the pharmaceutical product receiver (e.g., through a tray of a blister card).
The pharmaceutical product receiver may move relative to the container to dispose the mechanical lock in its inactive state in response to activating at least one release actuator. In one embodiment, each release actuator includes a cam or an angled surface. Actuating at least one release actuator causes an engaged portion of the pharmaceutical product receiver (e.g., an edge thereof) to advance along the cam or angled surface. This induces a relative motion between the pharmaceutical product receiver and the container to disengage the first and second locking members (e.g., by lifting the pharmaceutical product receiver such that the projection of the container no longer extends within the aperture of the pharmaceutical product receiver). A motion of the at least one release actuator in one direction may produce motion of the pharmaceutical product receiver in a different direction.
Any feature of any of the various aspects of the present invention that is intended to be limited to a “singular” context or the like will be clearly set forth herein by terms such as “only,” “single,” “limited to,” or the like. Merely introducing a feature in accordance with commonly accepted antecedent basis practice does not limit the corresponding feature to the singular (e.g., indicating that a pharmaceutical product supply includes “a pharmaceutical product receiver” alone does not mean that the pharmaceutical product supply includes only a single pharmaceutical product receiver). Moreover, any failure to use phrases such as “at least one” also does not limit the corresponding feature to the singular (e.g., indicating that pharmaceutical product supply includes “a pharmaceutical product receiver” alone does not mean that the pharmaceutical product supply includes only a single pharmaceutical product receiver). Use of the phrase “at least generally” or the like in relation to a particular feature encompasses the corresponding characteristic and insubstantial variations thereof (e.g., indicating that a panel is at least generally flat encompasses the panel being flat). Finally, a reference of a feature in conjunction with the phrase “in one embodiment” does not limit the use of the feature to a single embodiment.
The container utilized by the various aspects may be characterized as “secondary packaging.” The container may be of any appropriate size, shape, configuration, and/or type. Moreover, the container may be formed from any appropriate material or combination of materials. Although the container could include an openable cover, the container may simply include an open end through which the pharmaceutical product receiver may be directed to withdraw the pharmaceutical product receiver from within the container (e.g., for a dosing event), as well as to insert the pharmaceutical product receiver back into the container (e.g., for storage).
The pharmaceutical product receiver utilized by the various aspects may be characterized as “primary packaging.” The pharmaceutical product receiver may be in the form of a blister card or blister packaging. Scoring or perforations could be provided between each adjacent pair of receptacles of the blister card. As such, a single “blister pack” could be removed from the remainder of the blister card and for any appropriate reason. However, the blister card could be configured so as to retain the collection of receptacles in a connected state or condition (whether or not pharmaceutical product has been removed from one or more of the receptacles).
The above-noted blister card may be in the form of a pre-formed tray or the like having a number of receptacles or pockets. Any appropriate number of receptacles may be incorporated by the blister card. The various receptacles may be disposed in any appropriate arrangement, for instance in the form of a matrix having a certain number of rows and a certain number of columns at the time the blister card is dispensed to a patient or other end user.
An appropriate covering may be positioned over each receptacle in the above-noted blister card tray to enclose the associated pharmaceutical product. Such a covering may be in the form of a film, a foil, paper, a sheet-like material, or the like. In any case, this covering may be secured to the tray in any appropriate manner to seal or enclose pharmaceutical product within each of the various receptacles (e.g., a single pharmaceutical product dose). In one embodiment, this covering is rupturable over each of the individual receptacles of the tray to gain access to the pharmaceutical product within the receptacle. Rupturing the covering that overlies one receptacle should not affect the covering over any of the other receptacles (e.g., pharmaceutical product in these other receptacles should remain enclosed with the tray by the covering). In another embodiment, the covering may be “peeled” away from at least part of the tray to expose pharmaceutical product in at least one receptacle. Although a single covering could be positioned over each of the various receptacles, individual coverings could be positioned over each individual receptacle.
A “pharmaceutical product” as used herein may generally define any material or substance used in the course of a medical treatment, medical diagnosis, therapy, or the provision of any other appropriate medical care. In one embodiment, each pharmaceutical product is in the form of a pill (e.g., a tablet or capsule).
A pharmaceutical product within the receptacles of the pharmaceutical product receiver may be in any appropriate form, in any appropriate dose, and of any appropriate type. A pharmaceutical product encompasses both a single-dose configuration (e.g., a single pill) and a multiple dose configuration (e.g., a plurality of pills). Pharmaceutical product may be in any appropriate form such as (but not limited to) pills, tablets, chewables, capsules, or the like. Further, a “pharmaceutical product” may refer to or include any “drug” as defined in Title 21 of the United States Code, Section 321(g)(1).
A representative blister card or pack is shown in
Pharmaceutical product 30 may be disposed in each receptacle 18 of the blister card 10, and as such the blister card 10 may be referred to as “primary packaging” for the pharmaceutical product 30. A covering 20 is disposed over each receptacle 18 to enclose the corresponding pharmaceutical product 30 (the covering 20 being “puckered” in
Various embodiments of secondary packaging for blister cards at least generally of the above-noted type will now be described. Collectively, the secondary packaging and any blister card disposed therein may be referred to as a “pharmaceutical product supply.” In any case, the embodiments that will be described include various locking arrangements that facilitate disposal of the secondary packaging with one or more blister cards retained therein. Although each of these embodiments include only a single blister card within secondary packaging, the locking arrangements should work to lock multiple blister cards within the secondary packaging.
One embodiment of a pharmaceutical product supply is shown in
The container 42 may be formed from any appropriate material or combination of materials, and may be of any appropriate configuration. In the illustrated embodiment, the container 42 includes an end panel 46 and an oppositely disposed open end 44. The blister card 10′ may be directed through this open end 44 to dispose the blister card 10′ within the container 42 for storage, as well as to at least partially remove the blister card 10′ from within the container 42 (e.g., to gain access to one or more receptacles 18, so as to be able to remove pharmaceutical product 30 from the blister card 10′ in the above-noted manner). An openable cover or flap (not shown) could be provided to selectively expose/block the open end 44.
The container 42 for the pharmaceutical product supply 40 further includes an upper panel 48, an oppositely disposed bottom panel 50, and a pair of side panels 52. A pair of release tabs 54 may be incorporated by the side panels 52 to allow the blister card 10′ to be removed from within the container 42. For instance, the release tabs 54 may be pressed toward one another to disable an internal retention mechanism of any appropriate type (not shown) such that the blister card 10′ may be pulled out of the container 42 through its open end 44. That is, the container 42 may incorporate an appropriate mechanism to releasably retain the blister card 10′ within the container 42. Activation of the release tabs 54 may temporarily disable or deactivate such a retention mechanism (e.g., by changing the same from a locked configuration to an unlocked configuration). Simply repositioning the blister card 10′ back within the container 42 may “reactivate” this retention mechanism. Although the release tabs 54 and the noted retention mechanism may be utilized, such may be eliminated in at least some cases. Moreover, although the release tabs 54 are shown as being disposed in opposing relation, such need not be the case in all instances.
The container 42 further includes what may be characterized as a locking tab, latch member, or detent 56. Generally, this locking tab 56 may be moved from an unlocked configuration to a locked configuration. Disposing the locking tab 56 in its locked configuration disposes the locking tab 56 within the slot 22′ of the blister card 10′ when it is appropriately positioned within the container 42 (e.g.,
The locking tab 56 may be incorporated by the container 42 in any appropriate manner to provide the above-noted function. In the illustrated embodiment, the locking tab 56 is formed as part of the upper panel 48 of the container 42. An appropriate hinge 58 (e.g., a living hinge) may allow the locking tab 56 to be moved relative to the remainder of the upper panel 48 to move the locking tab 56 from its unlocked configuration of
Although the interaction between the locking tab 56 of the container 42 and the slot 22′ of the blister card 10′ may be sufficient to “lock” the blister card 10′ within the container 42, one or more additional retention features or the like may be utilized by the pharmaceutical product supply 40. For instance, a latch member 60 may be incorporated within the interior of the container 42 to impede a movement of the locking tab 56 that would dispose the same back into its unlocked configuration (e.g.,
Another embodiment of a pharmaceutical product supply is shown in
The container 72 may be formed from any appropriate material or combination of materials, and may be of any appropriate configuration. In the illustrated embodiment, the container 72 includes an end panel 76 and an oppositely disposed open end 74. The blister card 10″ may be directed through this open end 74 to dispose the blister card 10″ within the container 72 for storage, as well as to at least partially remove the blister card 10″ from within the container 72 (e.g., to gain access to one or more receptacles 18, so as to be able to remove pharmaceutical product 30 from the blister card 10″ in the above-noted manner). An openable cover or flap (not shown) could be provided to selectively expose/block the open end 74.
The container 72 for the pharmaceutical product supply 70 further includes an upper panel 78, an oppositely disposed bottom panel 80, and a pair of side panels 82. A pair of release tabs 84 may be incorporated by the side panels 82 to allow the blister card 10″ to be selectively removed from the container 72. When the blister card 10″ is disposed within the container 72, and while the release tabs 84 are disengaged or deactivated, the blister card 10″ is at least somewhat locked within the container 72—the blister card 10″ should not be able to be withdrawn from the container 72 through its open end 74. Activating the release tabs 84, however, does allow the blister card 10″ to be able to be withdrawn from the container 72 through its open end 74.
The release tabs 84 provide an additional function in the case of the pharmaceutical product supply 70—preparing the pharmaceutical product supply 74 for disposal. Removing and/or disabling one or more of the release tabs 84, with the blister card 10″ being appropriately positioned within the container 72, should inhibit the blister card 10″ from thereafter being removed from the container 72 in the intended manner (e.g., by attempting to pull the blister card 10″ out through the open end 74 of the container 72). That is, the blister card 10″ is at least somewhat locked within the container 72. However, it should be appreciated that the described locking arrangement does not preclude rupturing the container 72 in some fashion to gain access to the blister card 10″ stored therein.
Activating the release tabs 84 moves the blister card 10″ relative to the container 72 in a manner/direction such that the blister card 10″ may be withdrawn from the container 72 through its open end 74. Referring now to
Each release tabs 84 includes a cam or angled surface 86 that may interface with the blister card 10″ (e.g., the tray 12″) to “lift” the blister card 10″ off of the locking post 88 of the container 72. Moving the release tab 84 shown in
The blister card 10″ may be reinserted back into the container 72, and once it is in an appropriate position the blister card 10″ should “seat” back on the locking post 88 of the container 72 (e.g., such that the locking post 88 once again extends up through the slot 22″). The blister card 10″ may be repeatedly removed from and inserted back into the container 72 in the above-noted manner. When it is time to dispose of the pharmaceutical product supply 70 and as noted above, one or both of the release tabs 84 may be at least partially removed from the container 72 and/or otherwise be disabled. If at least one release tab 84 is removed/disabled and if the blister card 10″ is positioned therein such that the locking post 88 of the container 72 extends through the slot 22″ of the blister card 10″, there should be at least some resistance to removal of the blister card 10″ out through the open end 74 of the container 72. If at least one release tab 84 is removed/disabled and if the blister card 10″ is thereafter positioned within the container 72 such that the locking post 88 of the container 72 extends through the slot 22″ of the blister card 10″, there should also be at least some resistance to removal of the blister card 10″ out through the open end 74 of the container 72 (e.g., a mechanical lock defined by an interaction of the locking post 84 and the slot 22″ may be configured so as to be permanently retained in an active, activated, or locked/locking state). That is, the same mechanism that is used to releasably retain the blister card 10″ within the secondary packaging 72 (namely the release tabs 84), is used to place the pharmaceutical product supply 70 in an enhanced configuration for disposal (e.g., removing and/or disabling one or more of the release tabs 84).
Based upon the foregoing, a number of mechanical locking arrangements are disclosed for secondary packaging that includes one or more blister cards. One or more locking components may be integrated into the structure of the secondary packaging (e.g., integral construction, such that there is no joint between a locking member and the remainder of the secondary packaging). The locking arrangement may be activated by a simple manual operation. Again, these locking arrangements are intended to reduce the potential of a blister card being removed from its secondary packaging in the intended manner. These locking arrangements do not address each and every way that once could envisioned regarding attempting to gain access to pharmaceutical product stored within secondary packaging.
The foregoing description of the present invention has been presented for purposes of illustration and description. Furthermore, the description is not intended to limit the invention to the form disclosed herein. Consequently, variations and modifications commensurate with the above teachings, and skill and knowledge of the relevant art, are within the scope of the present invention. The embodiments described hereinabove are further intended to explain best modes known of practicing the invention and to enable others skilled in the art to utilize the invention in such, or other embodiments and with various modifications required by the particular application(s) or use(s) of the present invention. It is intended that the appended claims be construed to include alternative embodiments to the extent permitted by the prior art.
This patent application is a non-provisional patent application of and claims priority to co-pending U.S. Provisional Patent Application Ser. No. 61/376,552, that is entitled “PHARMACEUTICAL PRODUCT BLISTER PACK LOCKABLE WITHIN SECONDARY PACKAGING,” and that was filed on Aug. 24, 2010.
| Number | Date | Country | |
|---|---|---|---|
| 61376552 | Aug 2010 | US |
